The Pulse Today
BREAKING
Sajib Pledges Aid for 50,000 Flood-Affected People in SonargaonMP Azharul Islam Mannan Distributes Relief Funds to Needy Families in SonargaonParliament Proposes Anti-Gambling Bill with Maximum 7-Year Prison PenaltyOpenAI Unveils 'Schedule' Feature to Boost Task Management in AI ChatbotPrime Minister Tareq Rahman Arrives in Dalian, China for Economic ForumEurope Confronts Intense Heatwave; Conditions Predicted to DeteriorateGold Prices Rise Again in Bangladesh Amid Global Market IncreaseSpaceX's Nasdaq Debut Values Company at Over $2 Trillion, Surpassing AmazonStudy Reveals AI Data Centers Contribute to Local Temperature IncreasesNarayanganj BNP Youth Wing Holds Rally to Welcome New Central CommitteeICT-2 Orders Production of Retired Major Mozaffar in Zia Assassination CaseTwelve Individuals Detained in Special Police Operation in HazaribaghBangladesh Reports 1 Dengue Death and 338 New Hospitalizations in 24 HoursBarber tragically killed in Jashore road accident after being hit by speeding truckNagad Partners with NRB Bank to Enhance Financial Services Across BangladeshChinese Medical Team Visits Rajshahi for Children's Heart Disease ScreeningRajshahi-Dhaka Rail Service Restored Following Acceptance of Students' DemandsTwo Arrested in Narail for Murder and Drug-Related OffensesRUET Central Library Now Offers Online Access to E-books and E-journalsRangpur Metropolitan Police Conducts June 2026 Crime Review MeetingGovernment Aid Offers Relief to Rajshahi Families Impacted by Natural DisastersMP SM Jilani's Efforts Resolve Three-Year Waterlogging Issue for 300 Gopalganj FamiliesBangladesh Sees 23.1% Increase in Remittance Inflows in Early JulyRailway TTE Suspended Following Assault on Rajshahi University StudentPolice Nab Two Drug Dealers with 11,800 Yaba Tablets in Uttara

Novartis Announces 3% Q2 Sales Growth to $14.4 Billion, Fueled by New Treatments

Novartis has announced that its second-quarter sales in 2026 have exceeded expectations, driven by the introduction of new treatments.

By Staff Correspondent
Share
Novartis says buoyed by new treatments in second quarter | Business
BSS

Novartis, the Swiss pharmaceuticals giant, has reported a 3% increase in sales for the second quarter of 2026, reaching $14.4 billion. This performance slightly surpassed analyst forecasts of $14 billion. The growth is largely attributed to the successful launch of new products, including Rhapsido, a treatment for chronic rashes, which has already generated $64 million in sales since its approval in the US and EU.

Despite facing patent expirations for key drugs like Entresto, a heart failure treatment that generated $7.7 billion in 2025, Novartis has managed to maintain strong sales. The company confirmed its targets for 2026 and aims for 'low single-digit' sales growth for the entire year.

However, net profit fell by 19% to $3.2 billion, primarily due to higher interest and tax expenses. The Basel-based company remains optimistic about its future performance, driven by the success of its new treatments.

Novartis's performance in the second quarter highlights the company's ability to adapt to market challenges, including patent expirations, by introducing new products that resonate with patients and healthcare providers.

The pharmaceutical industry is witnessing a shift towards innovative treatments, and Novartis's recent success underscores the importance of continuous research and development in maintaining a competitive edge.

Source: BSS

Topics

Comments

More in business

See all →

Latest stories